Financial Ratios Zhongzhi Pharmaceutical Holdings Limited
Equities
3737
KYG989611085
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8700 HKD | -1.14% |
|
+8.75% | +55.36% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.86 | 3.38 | 3.81 | 5.59 | 4.14 | |||||
Return on Total Capital | 9.75 | 4.77 | 5.74 | 8.52 | 6.16 | |||||
Return On Equity % | 17.49 | 6.08 | 11.21 | 15.94 | 8.84 | |||||
Return on Common Equity | 17.5 | 6.07 | 11.19 | 15.87 | 8.8 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 61.79 | 60.77 | 58.45 | 59.25 | 57.85 | |||||
SG&A Margin | 49.29 | 53.37 | 50.09 | 48.53 | 49.42 | |||||
EBITDA Margin % | 13.01 | 7 | 8.43 | 10.48 | 7.78 | |||||
EBITA Margin % | 9.28 | 4.74 | 5.71 | 8.04 | 5.66 | |||||
EBIT Margin % | 9.24 | 4.56 | 5.67 | 8 | 5.65 | |||||
Income From Continuing Operations Margin % | 8.64 | 3 | 5.86 | 8.01 | 4.34 | |||||
Net Income Margin % | 8.64 | 2.98 | 5.83 | 7.94 | 4.3 | |||||
Net Avail. For Common Margin % | 8.64 | 2.98 | 5.83 | 7.94 | 4.3 | |||||
Normalized Net Income Margin | 6.49 | 3.61 | 4.34 | 6.13 | 4.36 | |||||
Levered Free Cash Flow Margin | -2.36 | -2.82 | 12.13 | -5.08 | 1.24 | |||||
Unlevered Free Cash Flow Margin | -2.16 | -2.57 | 12.35 | -4.84 | 1.44 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.19 | 1.19 | 1.07 | 1.12 | 1.17 | |||||
Fixed Assets Turnover | 3.91 | 3.57 | 3.26 | 3.31 | 3.18 | |||||
Receivables Turnover (Average Receivables) | 6.1 | 6.06 | 6.03 | 6.41 | 5.77 | |||||
Inventory Turnover (Average Inventory) | 2.75 | 2.66 | 2.57 | 2.56 | 2.76 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.82 | 1.71 | 1.49 | 1.44 | 1.39 | |||||
Quick Ratio | 1.23 | 1.13 | 0.97 | 0.87 | 0.89 | |||||
Operating Cash Flow to Current Liabilities | 0.19 | 0.36 | 0.39 | 0.17 | 0.25 | |||||
Days Sales Outstanding (Average Receivables) | 60 | 60.26 | 60.48 | 56.94 | 63.42 | |||||
Days Outstanding Inventory (Average Inventory) | 133.24 | 137.22 | 142.17 | 142.67 | 132.4 | |||||
Average Days Payable Outstanding | 59.46 | 59.77 | 69.69 | 82.49 | 93.92 | |||||
Cash Conversion Cycle (Average Days) | 133.77 | 137.71 | 132.97 | 117.11 | 101.91 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 22.87 | 19.5 | 16.98 | 16.6 | 16.82 | |||||
Total Debt / Total Capital | 18.61 | 16.32 | 14.52 | 14.24 | 14.4 | |||||
LT Debt/Equity | 8.91 | 8.95 | 9.41 | 9.42 | 9.53 | |||||
Long-Term Debt / Total Capital | 7.25 | 7.49 | 8.04 | 8.08 | 8.16 | |||||
Total Liabilities / Total Assets | 42.15 | 40.87 | 46.36 | 41.24 | 43.56 | |||||
EBIT / Interest Expense | 28.4 | 11.24 | 15.79 | 20.83 | 17.89 | |||||
EBITDA / Interest Expense | 47.1 | 23.25 | 30.07 | 33.48 | 33.35 | |||||
(EBITDA - Capex) / Interest Expense | 25.25 | -3 | 16.58 | 11.98 | 13.23 | |||||
Total Debt / EBITDA | 0.76 | 1.07 | 0.87 | 0.66 | 0.81 | |||||
Net Debt / EBITDA | -0.5 | -0.5 | -1.14 | -0.07 | -0.05 | |||||
Total Debt / (EBITDA - Capex) | 1.43 | -8.28 | 1.57 | 1.86 | 2.04 | |||||
Net Debt / (EBITDA - Capex) | -0.93 | 3.87 | -2.07 | -0.19 | -0.12 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 19.5 | 8.89 | 4.55 | 12.26 | 8.05 | |||||
Gross Profit, 1 Yr. Growth % | 18.8 | 7.09 | 0.57 | 13.8 | 5.49 | |||||
EBITDA, 1 Yr. Growth % | 25.29 | -39.96 | 28.53 | 39.61 | -19.96 | |||||
EBITA, 1 Yr. Growth % | 8.71 | -42.44 | 29.99 | 57.9 | -24.15 | |||||
EBIT, 1 Yr. Growth % | 8.37 | -43.61 | 30.07 | 58.37 | -23.88 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 20.86 | -62.22 | 104.17 | 53.52 | -41.42 | |||||
Net Income, 1 Yr. Growth % | 20.78 | -62.37 | 104.09 | 53 | -41.51 | |||||
Normalized Net Income, 1 Yr. Growth % | 13.19 | -36.71 | 25.51 | 58.74 | -23.3 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 21.45 | -64.1 | 109.34 | 51.27 | -42.11 | |||||
Accounts Receivable, 1 Yr. Growth % | 16.61 | 3.7 | 6.13 | 5.27 | 34.02 | |||||
Inventory, 1 Yr. Growth % | 24.16 | 8.47 | 20.46 | 2.2 | 4.65 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.08 | 26.69 | 4.8 | 15.78 | 9.99 | |||||
Total Assets, 1 Yr. Growth % | 10.93 | 7.29 | 23.04 | -4.41 | 10.85 | |||||
Tangible Book Value, 1 Yr. Growth % | 7.51 | 9.99 | 12.19 | 4.74 | 6.82 | |||||
Common Equity, 1 Yr. Growth % | 7.44 | 9.58 | 11.6 | 4.54 | 6.49 | |||||
Cash From Operations, 1 Yr. Growth % | -44.48 | 91.44 | 59.53 | -64.33 | 78.79 | |||||
Capital Expenditures, 1 Yr. Growth % | 99.39 | 63.04 | -52.43 | 91.36 | -16.8 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -159.98 | 16.49 | -549.14 | -142.44 | -126.57 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -152.73 | 14.89 | -602.53 | -139.77 | -132.31 | |||||
Dividend Per Share, 1 Yr. Growth % | -42.39 | - | - | 53.92 | -42.49 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 18.5 | 14.07 | 6.7 | 8.34 | 10.13 | |||||
Gross Profit, 2 Yr. CAGR % | 18.7 | 12.79 | 3.78 | 6.98 | 9.57 | |||||
EBITDA, 2 Yr. CAGR % | 42.7 | -14.29 | -13.09 | 33.96 | 5.83 | |||||
EBITA, 2 Yr. CAGR % | 37.97 | -22.21 | -14.87 | 43.27 | 9.6 | |||||
EBIT, 2 Yr. CAGR % | 37.67 | -23.72 | -14.36 | 43.53 | 9.95 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 27.65 | -32.43 | -12.18 | 77.04 | -5.17 | |||||
Net Income, 2 Yr. CAGR % | 27.61 | -32.58 | -12.37 | 76.71 | -5.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | 30.22 | -17.19 | -10.88 | 41.15 | 10.47 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 29.29 | -33.97 | -13.31 | 77.95 | -6.42 | |||||
Accounts Receivable, 2 Yr. CAGR % | 32.18 | 9.97 | 4.91 | 5.7 | 18.78 | |||||
Inventory, 2 Yr. CAGR % | 17.5 | 16.05 | 14.31 | 10.96 | 3.42 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 29.79 | 18.63 | 15.23 | 10.16 | 12.85 | |||||
Total Assets, 2 Yr. CAGR % | 18.51 | 9.1 | 14.9 | 8.45 | 2.94 | |||||
Tangible Book Value, 2 Yr. CAGR % | 7.14 | 8.74 | 11.09 | 8.4 | 5.77 | |||||
Common Equity, 2 Yr. CAGR % | 7.74 | 8.5 | 10.58 | 8.01 | 5.51 | |||||
Cash From Operations, 2 Yr. CAGR % | 8.04 | 3.1 | 74.76 | -24.57 | -20.14 | |||||
Capital Expenditures, 2 Yr. CAGR % | 23.12 | 80.3 | -11.93 | -4.59 | 26.18 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 60.77 | -11.65 | 128.74 | 45.26 | -66.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 54.48 | -17.33 | 140.28 | 48.61 | -64.2 | |||||
Dividend Per Share, 2 Yr. CAGR % | -12.66 | - | 30.52 | - | -5.91 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 19.3 | 15.21 | 10.8 | 8.52 | 8.24 | |||||
Gross Profit, 3 Yr. CAGR % | 20.86 | 14.7 | 8.56 | 7.01 | 6.48 | |||||
EBITDA, 3 Yr. CAGR % | 29.16 | 6.09 | -2.59 | 1.79 | 12.91 | |||||
EBITA, 3 Yr. CAGR % | 25.98 | 1.95 | -8.66 | 4.6 | 16.01 | |||||
EBIT, 3 Yr. CAGR % | 25.8 | 0.58 | -8.87 | 5.12 | 16.29 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 25.54 | -14.93 | -2.31 | 5.79 | 22.45 | |||||
Net Income, 3 Yr. CAGR % | 25.52 | -15.06 | -2.48 | 5.52 | 22.24 | |||||
Normalized Net Income, 3 Yr. CAGR % | 22.6 | 0.9 | -4.88 | 8.03 | 15.27 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 24.36 | -15.66 | -3 | 4.36 | 22.39 | |||||
Accounts Receivable, 3 Yr. CAGR % | 33.75 | 21.91 | 8.67 | 5.03 | 14.4 | |||||
Inventory, 3 Yr. CAGR % | 21.46 | 14.41 | 17.5 | 10.12 | 8.81 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 28.58 | 28.75 | 13.83 | 15.41 | 10.1 | |||||
Total Assets, 3 Yr. CAGR % | 15.92 | 14.64 | 13.56 | 8.06 | 9.25 | |||||
Tangible Book Value, 3 Yr. CAGR % | 6.78 | 8.08 | 9.88 | 8.93 | 7.87 | |||||
Common Equity, 3 Yr. CAGR % | 7.07 | 8.35 | 9.53 | 8.53 | 7.5 | |||||
Cash From Operations, 3 Yr. CAGR % | 22.1 | 30.74 | 19.25 | 2.89 | 0.58 | |||||
Capital Expenditures, 3 Yr. CAGR % | 34.66 | 35.21 | 15.64 | 14.07 | -8.85 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 58.99 | 49.83 | 51.91 | 34.96 | -17.62 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 54.29 | 45.7 | 50.87 | 36.39 | -10.73 | |||||
Dividend Per Share, 3 Yr. CAGR % | -2.89 | - | -0.63 | 37.9 | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 18.44 | 19.05 | 14.09 | 12.41 | 10.54 | |||||
Gross Profit, 5 Yr. CAGR % | 21.45 | 21.59 | 13.71 | 11.54 | 8.96 | |||||
EBITDA, 5 Yr. CAGR % | 14.33 | 12.31 | 9.71 | 15.96 | 0.69 | |||||
EBITA, 5 Yr. CAGR % | 10.4 | 12.1 | 6.98 | 16.07 | -1.76 | |||||
EBIT, 5 Yr. CAGR % | 10.31 | 11.2 | 6.81 | 15.95 | -1.76 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 11.47 | -0.57 | 8.82 | 14.05 | -3.47 | |||||
Net Income, 5 Yr. CAGR % | 11.46 | -0.66 | 8.71 | 13.86 | -3.65 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10.44 | 7.83 | 6.98 | 15.4 | 0.99 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 7.56 | -2.27 | 7.64 | 13.7 | -4.38 | |||||
Accounts Receivable, 5 Yr. CAGR % | 38.06 | 35.67 | 21.37 | 15.15 | 12.61 | |||||
Inventory, 5 Yr. CAGR % | 19.86 | 17.23 | 18.55 | 13.02 | 11.65 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 37.12 | 24.9 | 23.07 | 20.96 | 13.44 | |||||
Total Assets, 5 Yr. CAGR % | 14.45 | 15.08 | 15.51 | 12.13 | 9.19 | |||||
Tangible Book Value, 5 Yr. CAGR % | 7.4 | 9.24 | 8.48 | 8.21 | 8.22 | |||||
Common Equity, 5 Yr. CAGR % | 7.83 | 9.6 | 8.46 | 8.21 | 7.9 | |||||
Cash From Operations, 5 Yr. CAGR % | 10.7 | 29.47 | 40.93 | 4.92 | 1.58 | |||||
Capital Expenditures, 5 Yr. CAGR % | 29.62 | 10.85 | 13.62 | 17.61 | 19.75 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 32.02 | -6.89 | 88 | 47.98 | -15.28 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 28.45 | -8.62 | 88.7 | 46.86 | -13.43 | |||||
Dividend Per Share, 5 Yr. CAGR % | 1.22 | - | 9.3 | 14.87 | -2.77 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















